var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies

RWE 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies

Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.

However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.

Some of the limitations of clinical trial results in terms of generalizability to the larger population include:

Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.

Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.

Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.

Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.

Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.

However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.

Share this story...

Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies2023-08-07T11:13:47+00:00

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

Real world evidence (RWE) is not a replacement for clinical trials. Clinical trials are considered the gold standard for assessing the safety and efficacy of medical treatments because they are designed to control for various factors that could influence the results, such as confounding variables and bias. In contrast, RWE is based on observations and data collected from real-world settings, where there may be many confounding factors that can affect the outcomes.

However, RWE can complement clinical trials by providing additional insights into the effectiveness and safety of medical treatments in real-world settings. RWE can help to identify potential safety concerns, as well as provide information about the effectiveness of treatments in patient populations that may not have been included in the clinical trials.

Furthermore, RWE can also help to inform the design of future clinical trials by providing information about the natural history of diseases and the characteristics of patient populations. RWE can also help to identify potential subgroups of patients that may benefit more from certain treatments.

In summary, RWE is not a replacement for clinical trials, but it can provide valuable complementary information to help inform clinical decision-making and optimize the use of medical treatments.

Share this story...

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?2023-08-07T22:40:10+00:00

RWE 101 – 4 Potential Uses for Improving Drug Development

RWE 101 – 4 Potential Uses for Improving Drug Development

Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.

Some of the opportunities of real world evidence in drug development include:

1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.

In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.

Share this story...

RWE 101 – 4 Potential Uses for Improving Drug Development2023-08-07T22:31:56+00:00

USA | FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials

Please login to view this page.

USA | FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials2022-08-07T16:35:01+00:00
Go to Top